Amendment No. 3 to Letter of Agreement between SmithKline Beecham Corporation and Quest Diagnostics Incorporated

Contract Categories: Business Finance › Modification Agreements
Summary

SmithKline Beecham Corporation (doing business as GlaxoSmithKline) and Quest Diagnostics Incorporated have agreed to extend the term of their existing Letter of Agreement. The new expiration date is the earlier of July 31, 2008, or when a new Global Clinical Trials Agreement is fully executed. All other terms of the original agreement remain unchanged. This amendment is effective upon signature by both parties in June 2008.

Read More Arrow
EX-10.7 8 c54355_ex10-7.htm c54355_ex10-7.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

Exhibit 10.7

CONFIDENTIAL

Amendment #3 to the
Letter of Agreement between
SmithKline Beecham Corporation and
Quest Diagnostics Incorporated

1.     

The purpose of this Amendment #3 to the Letter of Agreement effective January 1, 2008 between SmithKline Beecham Corporation d/b/a GlaxoSmithKline and Quest Diagnostics Incorporated (hereinafter the “LOA”) is to extend the term referenced in section 2 of the LOA to the earlier of (i) July 31, 2008, or (ii) the full execution of a new comprehensive Global Clinical Trials Agreement.
 
2.     

All other terms and conditions of the LOA shall remain in full force and effect.
 
3.     

The parties hereto agree to this Amendment #3 to the LOA by their authorized signatures below.
 
SMITHKLINE BEECHAM CORPORATION   QUEST DIAGNOSTICS INCORPORATED  
 
 
/s/ Paula M. Russella   /s/ Daniel P. Megronigle  
Paula M. Russella   Daniel P. Megronigle  
Sourcing Group Manager   Executive Director, Sales & Marketing  
 
June 26, 2008   25 June 2008   
Date   Date